Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 1.00 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 11/20 | 0.71 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2544373 | 1.00 | PIM1 (1.00) | PIM1PIM2CISD1HPGDAKR1B1 | |
| SCHEMBL2544372 | 1.00 | PIM1 (1.00) | PIM1PIM2CISD1HPGDAKR1B1 | |
| SCHEMBL8714351 | 0.89 | PIM1 (0.80) | PIM1PIM2CISD1NPC1RAB9A | |
| SCHEMBL8714355 | 0.89 | PIM1 (0.80) | PIM1PIM2CISD1NPC1RAB9A | |
| SCHEMBL9570682 | 0.88 | PIM1 (0.78) | PIM1PIM2CISD1HPGDMAOA | |
| SCHEMBL2546354 | 0.88 | PIM1 (1.00) | PIM1PIM2CISD1HPGDAKR1B1 | |
| SCHEMBL1299479 | 0.88 | PIM1 (1.00) | PIM1PIM2CISD1HPGDAKR1B1 | |
| SCHEMBL9570687 | 0.88 | PIM1 (0.78) | PIM1PIM2CISD1HPGDMAOA | |
| SCHEMBL1299480 | 0.88 | PIM1 (1.00) | PIM1PIM2CISD1HPGDAKR1B1 | |
| SCHEMBL8182611 | 0.87 | HPGD (0.80) | PIM1PIM2CISD1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12076363-B2 | Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers | ONYX PHARMACEUTICALS, INC. (US) | 2024-09-03 | — | — | US | claimed |
| US-20200289606-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS INC (US) | 2020-09-17 | — | — | US | claimed |
| US-20190224270-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS INC (US) | 2019-07-25 | — | — | US | claimed |
| EP-3021862-B1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS INC (US) | 2017-08-30 | — | — | EP | claimed |
| US-20160166632-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS INC (US) | 2016-06-16 | — | — | US | claimed |
| EP-3021862-A2 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | Onyx Therapeutics, Inc. (US) | 2016-05-25 | — | — | EP | claimed |
| WO-2015009888-A2 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS, INC. (US) | 2015-01-22 | — | — | WO | claimed |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | claimed |
| EP-2217235-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | Musc Foundation for Research Development (US) | 2010-08-18 | — | — | EP | claimed |
| WO-2009064486-A9 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUND FOR RES DEV (US) | 2009-07-16 | — | — | WO | claimed |
| WO-2009064486-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2009-05-22 | — | — | WO | claimed |
| US-12076363-B2 | Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers | ONYX PHARMACEUTICALS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20220265758-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| US-11389440-B2 | PIM kinase inhibitors in combination with autophagy inhibitors for treatment of cancers | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3432886-B1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIV MARYLAND (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2217235-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | Musc Foundation for Research Development (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009064486-A9 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUND FOR RES DEV (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009064486-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289606-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885CISD1 2530/4885 |
| US-12076363-B2 | Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885CISD1 2530/4885 |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885CISD1 3097/4885 |
| US-20160166632-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885CISD1 2530/4885 |
| US-20190224270-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885CISD1 2530/4885 |
| US-20220265758-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885CISD1 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.